O	0	3	The	The	DT	B-NP
O	4	8	role	role	NN	I-NP
O	9	11	of	of	IN	B-PP
B-Organ	12	17	organ	organ	NN	B-NP
O	18	33	vascularization	vascularization	NN	I-NP
O	34	37	and	and	CC	I-NP
O	38	46	lipoplex	lipoplex	NN	I-NP
O	46	47	-	-	HYPH	B-NP
B-Organism_substance	47	52	serum	serum	NN	I-NP
O	53	60	initial	initial	JJ	I-NP
O	61	68	contact	contact	NN	I-NP
O	69	71	in	in	IN	B-PP
B-Immaterial_anatomical_entity	72	83	intravenous	intravenous	JJ	B-NP
O	84	90	murine	murine	JJ	I-NP
O	91	102	lipofection	lipofection	NN	I-NP
O	102	103	.	.	.	O

O	104	113	Following	Follow	VBG	B-VP
B-Immaterial_anatomical_entity	114	125	intravenous	intravenous	JJ	B-NP
O	126	140	administration	administration	NN	I-NP
O	141	143	of	of	IN	B-PP
O	144	152	cationic	cationic	JJ	B-NP
O	153	158	lipid	lipid	NN	I-NP
O	158	159	-	-	HYPH	B-NP
O	159	162	DNA	DNA	NN	I-NP
O	163	172	complexes	complex	NNS	I-NP
O	173	174	(	(	(	O
O	174	184	lipoplexes	lipoplex	NNS	B-NP
O	184	185	)	)	)	O
O	186	190	into	into	IN	B-PP
O	191	195	mice	mouse	NNS	B-NP
O	195	196	,	,	,	O
O	197	209	transfection	transfection	NN	B-NP
O	210	211	(	(	(	O
O	211	222	lipofection	lipofection	NN	B-NP
O	222	223	)	)	)	O
O	224	230	occurs	occur	VBZ	B-VP
O	231	244	predominantly	predominantly	RB	B-ADVP
O	245	247	in	in	IN	B-PP
O	248	251	the	the	DT	B-NP
B-Organ	252	257	lungs	lung	NNS	I-NP
O	257	258	.	.	.	O

O	259	263	This	This	DT	B-NP
O	264	267	was	be	VBD	B-VP
O	268	278	attributed	attribute	VBN	I-VP
O	279	281	to	to	TO	B-PP
O	282	286	high	high	JJ	B-NP
O	287	297	entrapment	entrapment	NN	I-NP
O	298	300	of	of	IN	B-PP
O	301	311	lipoplexes	lipoplex	NNS	B-NP
O	312	314	in	in	IN	B-PP
O	315	318	the	the	DT	B-NP
O	319	327	extended	extend	VBN	I-NP
B-Multi-tissue_structure	328	332	lung	lung	NN	I-NP
I-Multi-tissue_structure	333	341	vascular	vascular	JJ	I-NP
I-Multi-tissue_structure	342	346	tree	tree	NN	I-NP
O	346	347	.	.	.	O

O	348	350	To	To	TO	B-VP
O	351	360	determine	determine	VB	I-VP
O	361	368	whether	whether	IN	B-SBAR
O	369	380	lipofection	lipofection	NN	B-NP
O	381	383	in	in	IN	B-PP
O	384	389	other	other	JJ	B-NP
B-Organ	390	396	organs	organ	NNS	I-NP
O	397	402	could	could	MD	B-VP
O	403	405	be	be	VB	I-VP
O	406	414	enhanced	enhance	VBN	I-VP
O	415	417	by	by	IN	B-PP
O	418	428	increasing	increase	VBG	B-VP
O	429	432	the	the	DT	B-NP
O	433	439	degree	degree	NN	I-NP
O	440	442	of	of	IN	B-PP
O	443	458	vascularization	vascularization	NN	B-NP
O	458	459	,	,	,	O
O	460	462	we	we	PRP	B-NP
O	463	467	used	use	VBD	B-VP
O	468	469	a	a	DT	B-NP
O	470	480	transgenic	transgenic	JJ	I-NP
O	481	486	mouse	mouse	NN	I-NP
O	487	492	model	model	NN	I-NP
O	493	497	with	with	IN	B-PP
B-Tissue	498	504	tissue	tissue	NN	B-NP
O	504	505	-	-	HYPH	B-NP
O	505	513	specific	specific	JJ	I-NP
O	514	526	angiogenesis	angiogenesis	NN	I-NP
O	527	529	in	in	IN	B-PP
B-Organ	530	535	liver	liver	NN	B-NP
O	535	536	.	.	.	O

B-Multi-tissue_structure	537	541	Tail	Tail	NN	B-NP
I-Multi-tissue_structure	542	546	vein	vein	NN	I-NP
O	547	556	injection	injection	NN	I-NP
O	557	559	of	of	IN	B-PP
O	560	561	N	N	NN	B-NP
O	561	562	-	-	HYPH	O
O	562	563	(	(	(	O
O	563	564	1	1	CD	O
O	564	565	-	-	HYPH	O
O	565	566	(	(	(	O
O	566	567	2	2	CD	B-NP
O	567	568	,	,	,	O
O	568	569	3	3	CD	B-NP
O	569	570	-	-	HYPH	I-NP
O	570	581	dioleoyloxy	dioleoyloxy	NN	I-NP
O	581	582	)	)	)	O
O	582	588	propyl	propyl	NN	B-NP
O	588	589	)	)	)	O
O	589	590	-	-	HYPH	B-NP
O	590	591	N	N	NN	I-NP
O	591	592	,	,	,	O
O	592	593	N	N	NN	B-NP
O	593	594	,	,	,	O
O	594	595	N	N	NN	B-NP
O	595	596	-	-	HYPH	O
O	596	613	trimethylammonium	trimethylammonium	NN	B-NP
O	614	622	chloride	chloride	NN	I-NP
O	623	624	(	(	(	O
O	624	629	DOTAP	DOTAP	NN	B-NP
O	629	630	)	)	)	O
O	630	631	/	/	SYM	B-NP
O	631	642	cholesterol	cholesterol	NN	I-NP
O	643	653	lipoplexes	lipoplex	NNS	I-NP
O	654	662	resulted	result	VBD	B-VP
O	663	665	in	in	IN	B-PP
O	666	675	increased	increase	VBN	B-NP
O	676	684	lipoplex	lipoplex	NN	I-NP
O	685	695	entrapment	entrapment	NN	I-NP
O	696	698	in	in	IN	B-PP
O	699	716	hypervascularized	hypervascularize	VBN	B-NP
B-Organ	717	722	liver	liver	NN	I-NP
O	723	726	but	but	CC	O
O	727	730	did	do	VBD	B-VP
O	731	734	not	not	RB	I-VP
O	735	740	boost	boost	VB	I-VP
O	741	751	luciferase	luciferase	NN	B-NP
O	752	762	expression	expression	NN	I-NP
O	762	763	,	,	,	O
O	764	774	suggesting	suggest	VBG	B-VP
O	775	779	that	that	IN	B-SBAR
O	780	788	lipoplex	lipoplex	NN	B-NP
O	789	797	delivery	delivery	NN	I-NP
O	798	800	is	be	VBZ	B-VP
O	801	804	not	not	RB	O
O	805	806	a	a	DT	B-NP
O	807	817	sufficient	sufficient	JJ	I-NP
O	818	827	condition	condition	NN	I-NP
O	828	831	for	for	IN	B-PP
O	832	841	efficient	efficient	JJ	B-NP
B-Organ	842	847	organ	organ	NN	I-NP
O	848	859	lipofection	lipofection	NN	I-NP
O	859	860	.	.	.	O

O	861	868	Because	Because	IN	B-SBAR
O	869	872	the	the	DT	B-NP
B-Immaterial_anatomical_entity	873	886	intravenously	intravenously	RB	I-NP
O	887	895	injected	inject	VBN	I-NP
O	896	906	lipoplexes	lipoplex	NNS	I-NP
O	907	915	migrated	migrate	VBD	B-VP
O	916	922	within	within	IN	B-PP
O	923	930	seconds	second	NNS	B-NP
O	931	933	to	to	TO	B-PP
B-Organ	934	939	lungs	lung	NNS	B-NP
O	939	940	,	,	,	O
O	941	943	we	we	PRP	B-NP
O	944	951	checked	check	VBD	B-VP
O	952	959	whether	whether	IN	B-SBAR
O	960	963	the	the	DT	B-NP
O	964	971	effects	effect	NNS	I-NP
O	972	974	of	of	IN	B-PP
O	975	984	immediate	immediate	JJ	B-NP
O	985	992	contact	contact	NN	I-NP
O	993	997	with	with	IN	B-PP
B-Organism_substance	998	1003	serum	serum	NN	B-NP
O	1004	1013	correlate	correlate	VBP	B-VP
O	1014	1018	with	with	IN	B-PP
B-Organ	1019	1023	lung	lung	NN	B-NP
O	1024	1035	lipofection	lipofection	NN	I-NP
O	1036	1046	efficiency	efficiency	NN	I-NP
O	1047	1049	of	of	IN	B-PP
O	1050	1059	different	different	JJ	B-NP
O	1060	1065	DOTAP	DOTAP	NN	I-NP
O	1065	1066	-	-	HYPH	B-NP
O	1066	1071	based	base	VBN	I-NP
O	1072	1084	formulations	formulation	NNS	I-NP
O	1084	1085	.	.	.	O

O	1086	1091	Under	Under	IN	B-PP
O	1092	1102	conditions	condition	NNS	B-NP
O	1103	1112	mimicking	mimic	VBG	B-VP
O	1113	1116	the	the	DT	B-NP
O	1117	1126	injection	injection	NN	I-NP
O	1127	1138	environment	environment	NN	I-NP
O	1138	1139	,	,	,	O
O	1140	1143	the	the	DT	B-NP
O	1144	1152	lipoplex	lipoplex	NN	I-NP
O	1152	1153	-	-	HYPH	B-NP
B-Organism_substance	1153	1158	serum	serum	NN	I-NP
O	1159	1170	interaction	interaction	NN	I-NP
O	1171	1174	was	be	VBD	B-VP
O	1175	1183	strongly	strongly	RB	B-ADJP
O	1184	1193	dependent	dependent	JJ	I-ADJP
O	1194	1196	on	on	IN	B-PP
O	1197	1203	helper	helper	NN	B-NP
O	1204	1209	lipid	lipid	NN	I-NP
O	1210	1213	and	and	CC	O
O	1214	1219	ionic	ionic	JJ	B-NP
O	1220	1228	strength	strength	NN	I-NP
O	1228	1229	:	:	:	O
O	1230	1240	lipoplexes	lipoplex	NNS	B-NP
O	1241	1249	prepared	prepare	VBN	B-VP
O	1250	1252	in	in	IN	B-PP
O	1253	1256	150	150	CD	B-NP
O	1257	1259	mM	mM	NN	I-NP
O	1260	1264	NaCl	NaCl	NN	I-NP
O	1265	1267	or	or	CC	O
O	1268	1278	lipoplexes	lipoplex	NNS	B-NP
O	1279	1283	with	with	IN	B-PP
O	1284	1288	high	high	JJ	B-NP
O	1289	1290	(	(	(	O
O	1291	1298	greater	great	JJR	B-ADJP
O	1299	1303	than	than	IN	B-PP
O	1304	1306	33	33	CD	B-NP
O	1307	1310	mol	mol	NN	I-NP
O	1310	1311	%	%	NN	I-NP
O	1311	1312	)	)	)	O
O	1313	1324	cholesterol	cholesterol	NN	B-NP
O	1325	1329	were	be	VBD	B-VP
O	1330	1335	found	find	VBN	I-VP
O	1336	1338	to	to	TO	I-VP
O	1339	1348	aggregate	aggregate	VB	I-VP
O	1349	1360	immediately	immediately	RB	B-ADVP
O	1360	1361	.	.	.	O

O	1362	1366	This	This	DT	B-NP
O	1367	1378	aggregation	aggregation	NN	I-NP
O	1379	1386	process	process	NN	I-NP
O	1387	1390	was	be	VBD	B-VP
O	1391	1403	irreversible	irreversible	JJ	B-ADJP
O	1404	1407	and	and	CC	O
O	1408	1411	was	be	VBD	B-VP
O	1412	1421	inversely	inversely	RB	I-VP
O	1422	1432	correlated	correlate	VBN	I-VP
O	1433	1437	with	with	IN	B-PP
O	1438	1441	the	the	DT	B-NP
O	1442	1452	percentage	percentage	NN	I-NP
O	1453	1455	of	of	IN	B-PP
B-Cell	1456	1460	lung	lung	NN	B-NP
I-Cell	1461	1466	cells	cell	NNS	I-NP
O	1467	1471	that	that	WDT	B-NP
O	1472	1476	took	take	VBD	B-VP
O	1477	1479	up	up	RP	B-PRT
O	1480	1490	lipoplexes	lipoplex	NNS	B-NP
O	1491	1494	and	and	CC	B-PP
O	1495	1499	with	with	IN	B-PP
O	1500	1503	the	the	DT	B-NP
O	1504	1514	efficiency	efficiency	NN	I-NP
O	1515	1517	of	of	IN	B-PP
O	1518	1529	lipofection	lipofection	NN	B-NP
O	1529	1530	.	.	.	O

O	1531	1533	No	No	DT	B-NP
O	1534	1539	other	other	JJ	I-NP
O	1540	1550	structural	structural	JJ	I-NP
O	1551	1558	changes	change	NNS	I-NP
O	1559	1561	in	in	IN	B-PP
B-Organism_substance	1562	1567	serum	serum	NN	B-NP
O	1568	1572	were	be	VBD	B-VP
O	1573	1581	observed	observe	VBN	I-VP
O	1582	1585	for	for	IN	B-PP
O	1586	1597	cholesterol	cholesterol	NN	B-NP
O	1597	1598	-	-	HYPH	B-NP
O	1598	1603	based	base	VBN	I-NP
O	1604	1614	lipoplexes	lipoplex	NNS	I-NP
O	1614	1615	.	.	.	O

O	1616	1624	Dioleoyl	Dioleoyl	NN	B-NP
O	1625	1649	phosphatidylethanolamine	phosphatidylethanolamine	NN	I-NP
O	1649	1650	-	-	HYPH	B-NP
O	1650	1655	based	base	VBN	I-NP
O	1656	1666	lipoplexes	lipoplex	NNS	I-NP
O	1667	1671	were	be	VBD	B-VP
O	1672	1677	found	find	VBN	I-VP
O	1678	1680	to	to	TO	I-VP
O	1681	1685	give	give	VB	I-VP
O	1686	1689	low	low	JJ	B-NP
O	1690	1700	expression	expression	NN	I-NP
O	1700	1701	,	,	,	O
O	1702	1712	apparently	apparently	RB	B-ADVP
O	1713	1720	because	because	IN	B-PP
O	1721	1723	of	of	IN	I-PP
O	1724	1726	an	an	DT	B-NP
O	1727	1736	immediate	immediate	JJ	I-NP
O	1737	1741	loss	loss	NN	I-NP
O	1742	1744	of	of	IN	B-PP
O	1745	1754	integrity	integrity	NN	B-NP
O	1755	1757	in	in	IN	B-PP
B-Organism_substance	1758	1763	serum	serum	NN	B-NP
O	1763	1764	,	,	,	O
O	1765	1772	without	without	IN	B-PP
O	1773	1778	lipid	lipid	NN	B-NP
O	1778	1779	-	-	HYPH	B-NP
O	1779	1782	DNA	DNA	NN	I-NP
O	1783	1795	dissociation	dissociation	NN	I-NP
O	1795	1796	.	.	.	O

O	1797	1800	Our	Our	PRP$	B-NP
O	1801	1806	study	study	NN	I-NP
O	1807	1815	suggests	suggest	VBZ	B-VP
O	1816	1820	that	that	IN	B-SBAR
O	1821	1830	efficient	efficient	JJ	B-NP
O	1831	1833	in	in	FW	I-NP
O	1834	1838	vivo	vivo	FW	I-NP
O	1839	1850	lipofection	lipofection	NN	I-NP
O	1851	1853	is	be	VBZ	B-VP
O	1854	1857	the	the	DT	B-NP
O	1858	1864	result	result	NN	I-NP
O	1865	1867	of	of	IN	B-PP
O	1868	1873	cross	cross	AFX	B-NP
O	1873	1874	-	-	HYPH	I-NP
O	1874	1878	talk	talk	NN	B-NP
O	1879	1886	between	between	IN	B-PP
O	1887	1895	lipoplex	lipoplex	NN	B-NP
O	1896	1907	composition	composition	NN	I-NP
O	1907	1908	,	,	,	O
O	1909	1920	interaction	interaction	NN	B-NP
O	1921	1925	with	with	IN	B-PP
B-Organism_substance	1926	1931	serum	serum	NN	B-NP
O	1931	1932	,	,	,	O
O	1933	1945	hemodynamics	hemodynamic	NNS	B-NP
O	1945	1946	,	,	,	O
O	1947	1950	and	and	CC	O
O	1951	1957	target	target	NN	B-NP
B-Tissue	1958	1964	tissue	tissue	NN	I-NP
O	1965	1966	"	"	``	B-NP
O	1966	1980	susceptibility	susceptibility	NN	I-NP
O	1980	1981	"	"	''	O
O	1982	1984	to	to	TO	B-PP
O	1985	1997	transfection	transfection	NN	B-NP
O	1997	1998	.	.	.	O

